The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II trial of pevonedistat plus docetaxel in patients with previously treated advanced non–small-cell lung cancer (NSCLC).
 
Leah Wells
Employment - Ashfield Healthcare (I); Syneos Health (I); Zoll (I)
 
Angel Qin
Consulting or Advisory Role - Amgen
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Merck Sharp & Dohme (Inst); Roche (Inst); Takeda (Inst); Xencor (Inst)
 
John Rice
No Relationships to Disclose
 
Shirish M. Gadgeel
Honoraria - Merck
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Bristol-Myers Squibb; Daichii-Sanyko; Eisai; Genentech/Roche; Gilead Sciences; GlaxoSmithKline; Janssen Oncology; Lilly; Merck; Mirati Therapeutics; Novartis; Pfizer; Takeda
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca; AstraZeneca (Inst); BioMed Valley Discoveries (Inst); Blueprint Medicines (Inst); Calithera Biosciences (Inst); Daichii Sanyko (Inst); Daiichi Sankyo (Inst); Dragonfly Therapeutics (Inst); eFFECTOR Therapeutics (Inst); Elevation Oncology (Inst); Erasca, Inc (Inst); Genentech/Roche (Inst); Helsinn Therapeutics (Inst); I-Mab (Inst); Incyte (Inst); InventisBio (Inst); Janssen Oncology (Inst); Merck; Merck (Inst); Mirati Therapeutics (Inst); Nektar (Inst); Nektar (Inst); Numab (Inst); Pfizer (Inst); Regeneron (Inst); Regeneron (Inst); Turning Point Therapeutics (Inst); Verastem (Inst); Ymabs Therapeutics Inc (Inst)
Travel, Accommodations, Expenses - Mirati Therapeutics
Other Relationship - AstraZeneca
 
Bryan J. Schneider
Research Funding - Bristol-Meyers-Squibb/Statistical Horizons (Inst); Genentech (Inst); Incyte (Inst)
 
Nithya Ramnath
Research Funding - Clovis Oncology (Inst); Clovis Oncology (Inst); Merck (Inst)
 
Lili Zhao
No Relationships to Disclose
 
Gregory Peter Kalemkerian
Consulting or Advisory Role - BioMed Valley Discoveries (I); Synlogic (I); Takeda (I)
Research Funding - Abbvie (Inst); Blueprint Medicines (Inst); Bristol Myers Squibb Foundation (Inst); Cullinan Oncology (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Merck (Inst); Takeda (Inst)